Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPM1 | P06748 | 2/20 | 0.47 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.47 |
| ▸ | PDE2A | O00408 | 9/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | PRKDC | P78527 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | TNF | P01375 | 1/20 | 0.34 |
| ▸ | GLP1R | P43220 | 1/20 | 0.34 |
| ▸ | IKBKB | O14920 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23119274 | 0.74 | ATM (0.44) | NPM1ALKRXFP1PIK3CBMTOR | |
| SCHEMBL23119361 | 0.73 | PRKDC (0.66) | PDE10APIK3CBMTORPRKDCATM | |
| SCHEMBL23119175 | 0.72 | ATM (0.39) | NPM1ALKPDE2APDE10ACYP1A2 | |
| SCHEMBL23119172 | 0.71 | NPM1 (0.43) | NPM1ALKPDE2APDE10ACASP3 | |
| SCHEMBL797783 | 0.70 | NPM1 (0.42) | NPM1ALKPDE2APDE10APIK3CB | |
| SCHEMBL29284757 | 0.70 | PDE2A (0.38) | NPM1ALKPDE2APDE10ACYP1A2 | |
| SCHEMBL17674019 | 0.66 | SMN1; SMN2 (0.58) | NPM1ALKPDE2APDE10ACYP1A2 | |
| SCHEMBL31473995 | 0.66 | SMN1; SMN2 (0.58) | NPM1ALKPDE2APDE10ACYP1A2 | |
| SCHEMBL960479 | 0.64 | ALDH1A1 (0.55) | NPM1ALKPDE2APDE10ACASP3 | |
| SCHEMBL29800116 | 0.64 | HSD17B10 (0.45) | NPM1ALKCYP1A2CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119215050-A | Application of substituted imidazoquinoxaline compound in preparation of anti-cancer drugs | 上海瑛派药业有限公司 | 2024-12-31 | — | — | CN | disclosed |
| CN-119080781-A | Substituted imidazoquinoxaline compounds and uses thereof | 上海瑛派药业有限公司 | 2024-12-06 | — | — | CN | disclosed |
| CN-114787162-B | Substituted imidazoquinoxaline compounds and uses thereof | 上海瑛派药业有限公司 | 2024-09-03 | — | — | CN | disclosed |
| US-20220354859-A1 | SUBSTITUTED IMIDAZOQUINOXALINE COMPOUNDS AND USES THEREOF | Impact Therapeutics (Shanghai), Inc (CN) | 2022-11-10 | — | — | US | disclosed |
| EP-4028400-A1 | SUBSTITUTED IMIDAZOQUINOXALINE COMPOUNDS AND USES THEREOF | Impact Therapeutics (Shanghai), Inc (CN) | 2022-07-20 | — | — | EP | disclosed |
| WO-2021047646-A1 | SUBSTITUTED IMIDAZOQUINOXALINE COMPOUNDS AND USES THEREOF | IMPACT THERAPEUTICS, INC (CN) | 2021-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220354859-A1 | SUBSTITUTED IMIDAZOQUINOXALINE COMPOUNDS AND USES THEREOF | CHEK2, CHEK1, ATM | NPM1 783/4885ALK 544/4885PDE2A 777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.